Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- 2019 Top Stories in Metastatic Breast Cancer: HER2+ Breast Cancer—A Double-Edged Sword
- Eribulin Mesylate Administered Biweekly in Patients With HER2- Metastatic Breast Cancer
- Abemaciclib Plus Fulvestrant Improves Overall Survival in HR+, ERBB2− Breast Cancer That Progressed on Endocrine Therapy
- PIK3CA and MAP3K1 Are Associated With Clinical Benefit From Buparlisib + Letrozole in ER+ MBC
- Trastuzumab Use in Older Patients With HER2+ MBC
- ESMO 2019: Recommendations From Dr. Reshma Mahtani
- Durvalumab in Combination With Trastuzumab in HER2‐Positive Metastatic Breast Cancer
- Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
- Irinotecan and Temozolomide in Breast Cancer Patients With Progressing CNS Disease
- Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for HR+ Metastatic Breast Cancer